PTC Therapeutics, Inc. Debt Securities, Available-for-sale, Amortized Cost
PTC Therapeutics, Inc. (PTCT) had Debt Securities, Available-for-sale, Amortized Cost of $1.15 billion as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes › Credit Losses
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-07-30
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $1.15B.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $1.01B.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $928.34M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $970.57M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $1.15B 10-Q · filed 2026-07-30 |
| 2026-03-31 | $1.01B 10-Q · filed 2026-05-07 |
| 2025-12-31 | $928.34M 10-Q · filed 2026-07-30 |
| 2025-09-30 | $970.57M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $937.57M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $518.58M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $330.68M 10-K · filed 2026-02-19 |
| 2024-09-30 | $455.57M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $421.86M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $306.20M 10-Q · filed 2024-04-25 |
| 2023-12-31 | $259.78M 10-K · filed 2025-02-27 |
| 2023-09-30 | $1.65M 10-Q · filed 2023-10-26 |
| 2023-06-30 | $1.65M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $10.69M 10-Q · filed 2023-04-27 |
| 2022-12-31 | $23.10M 10-K · filed 2024-02-29 |
| 2022-09-30 | $73.93M 10-Q · filed 2022-10-27 |
| 2022-06-30 | $158.64M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $248.34M 10-Q · filed 2022-05-03 |
| 2021-12-31 | $377.29M 10-K · filed 2023-02-21 |
| 2021-09-30 | $471.94M 10-Q · filed 2021-10-28 |
| 2021-06-30 | $568.51M 10-Q · filed 2021-07-29 |
| 2021-03-31 | $641.47M 10-Q · filed 2021-05-04 |
| 2020-12-31 | $892.94M 10-K · filed 2022-02-22 |
| 2020-09-30 | $704.65M 10-Q · filed 2020-10-29 |
| 2020-06-30 | $337.02M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $471.96M 10-Q · filed 2020-04-30 |
| 2019-12-31 | $397.78M 10-K · filed 2021-02-25 |
| 2019-09-30 | $184.32M 10-Q · filed 2019-10-30 |
| 2019-06-30 | $226.80M 10-Q · filed 2019-08-06 |
| 2019-03-31 | $205.95M 10-Q · filed 2019-05-02 |
| 2018-12-31 | $58.06M 10-K · filed 2020-03-02 |
| 2018-09-30 | $42.52M 10-Q · filed 2018-11-05 |
| 2018-06-30 | $72.38M 10-Q · filed 2018-08-07 |
| 2017-12-31 | $79.43M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |